AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

SRPT · NASDAQ · Biotechnology

Sarepta Therapeutics (SRPT)

Develops Duchenne muscular dystrophy medicines and genetic therapies for rare diseases.

$19.42

vs last close−1.39 (−6.66%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	332	397	413	363	467	658	745	611	399	443	731	401
Cost of revenue	37	44	51	45	92	132	138	153	151	399	119	149
Gross profit	295	353	363	318	375	526	607	459	249	44	611	252
	316	328	328	319	353	364	908	343	352	456	253	239
Research & development	194	196	200	180	224	200	773	204	219	325	154	91
	121	132	127	139	128	164	134	138	92	128	109	108
General & administrative	121	132	127	139	128	164	134	138	92	128	109	0
Other expenses	0	1	1	1	1	1	1	1	41	2	−10	40
Operating income	−21	25	35	−1	22	162	−300	116	−103	−412	358	13
	−12	16	7	14	12	10	−83	38	−91	133	−15	−15
Interest income	23	23	20	19	18	15	12	7	8	8	7	6
Interest expense	5	5	4	5	5	4	5	5	8	8	22	22
Other non-operating income	7	−21	−11	−19	−17	−15	79	−43	83	−154	−6	−6
Income before tax	−33	40	41	14	34	172	−384	154	−194	−278	343	−2
Income tax expense	8	−5	5	7	0	13	64	−43	−14	5	12	3
Net income from continuing operations	−41	46	36	6	34	159	−448	197	−180	−283	331	−5
Net income	−41	46	36	6	34	159	−448	197	−180	−283	331	−5
EPS, basic	−$0.46	$0.49	$0.38	$0.07	$0.35	$1.65	−$4.60	$2.01	−$1.80	−$2.74	$3.15	−$0.05
EPS, diluted	−$0.46	$0.43	$0.37	$0.07	$0.33	$1.50	−$4.60	$1.89	−$1.80	−$3.93	$2.88	−$0.05
Weighted average shares, basic	89	94	94	95	95	96	97	98	100	105	105	105
Weighted average shares, diluted	89	106	99	99	100	108	97	107	100	105	122	105
EBITDA	−17	57	54	27	49	187	−369	170	−168	−252	375	30
Depreciation & amortization	11	11	9	9	10	10	10	11	18	5	11	10
EBIT	−28	46	46	18	39	176	−379	159	−186	−257	365	20